Clinical journal of oncology nursing最新文献

Background: Patients with multiple myeloma undergoing autologous stem cell transplantation are vulnerable to physical deconditioning during hospitalization.

Objectives: This randomized controlled pilot study evaluated the effect of real-time feedback on inpatient ambulation using wearable activity monitors on step counts and fitness at discharge.

Methods: Patients received wearable activity monitors to measure step counts and completed the 6-Minute Walk Test and SF-36® pre- and postadmission. Patients were randomized to the feedback group (N = 11) that received real-time televised feedback on step counts or the control group (N = 9) that received standard care.

Findings: Patients in the feedback group had higher average daily step counts. Each additional access of the ambulation dashboard correlated with an increase of 137 steps per day, suggesting that consistent feedback could potentially improve ambulation after transplantation.

The neutropenic diet is an infection prevention method often employed for neutropenic patients with cancer. The overall efficacy of the diet remains unclear despite its frequent prescription. Oncology nurses at all practice l.

This article explores the economic burdens experienced by people with cancer and presents evidence-based solutions to mitigate financial hardships. An analysis of contributing factors like treatment costs and demographic ineq.

Background: Chemotherapy agents like ifosfamide can cause dose-limiting renal and central nervous system (CNS) toxicities. Routinely assessing for CNS changes associated with ifosfamide was not standard nursing practice, and the lack of provider and nursing knowledge of subtle CNS changes was identified as a safety factor that needed improving.

Objectives: The purpose of this quality improvement project was to implement an evidence-based nursing assessment tool to provide early identification of ifosfamide toxicity.

Methods: The project team created an internal tool incorporating the Common Terminology Criteria for Adverse Events to categorize and grade toxicity symptoms. Nurses used the tool to assess patients' renal and CNS baselines and monitor for 13 potential symptoms throughout ifosfamide administration.

Findings: Acute care oncology nurses felt empowered to report subtle CNS changes when using the tool, leading to early identification of ifosfamide toxicity.

Background: Genetic testing for heritable germline variants in BRCA1/BRCA2 genes informs risk assessment and treatment decisions and often involves a non-nursing oncology multidisciplinary team, which offers pretest counseling, obtains patient consent, and arranges genetic testing.

Objectives: This review, initiated by a collaboration of international nurses, summarizes the potential roles of oncology nurses in the genetic testing pathway, including germline BRCA testing.

Methods: Literature discussing nurses' roles in germline BRCA testing and genomic testing in general was screened, which resulted in 33 studies being selected for further analysis.

Findings: The literature demonstrates the value of nurses obtaining patient consent and samples and providing pre- and post-test counseling and follow-up care, which can help to improve wait times and educate patients about their cancer risks to make informed healthcare decisions. Nurses mostly felt that genetic testing did not negatively affect their workloads. Concerns over nonspecialists delivering pretest counseling exist, and specialized training is required, although patients were satisfied with the information nurses provided.

Background: The standard of care for hormone receptor-positive breast cancer often involves prolonged use of ovarian function suppression (OFS) therapies, including goserelin. Manufacturer recommendations instruct nurses to inject goserelin subcutaneously into the anterior abdominal wall, below the navel line. However, certain patients may be inclined to avoid abdominal injections because of their surgical histories or personal preferences.

Objectives: This study examines the patient outcomes for goserelin injections at alternative injection sites (AISs) in premenopausal patients with estrogen receptor-positive breast cancer.

Methods: A retrospective chart review was conducted to identify premenopausal women with estrogen receptor-positive breast cancer who received goserelin at an AIS. Absence of menses was a surrogate marker estimating OFS performance.

Findings: Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.

Cancer care has advanced during the past three decades. Despite improved survival, pancreatic cancer has failed to make much progress in diagnosis and treatment, and it remains one of the most fatal cancers. Clinicians have r.

Background: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.

Objectives: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab.

Methods: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed.

Findings: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent.

Tumor-agnostic cancer therapies look beyond the cancer's tissue of origin and histology, instead focusing on targeting genomic alterations that drive cancer growth and progression across multiple tumor types. Eight drugs or.

About the AuthorEllen Dermody, MSN, RN, OCN®, ONN-CG, NC-BC, is a holistic care partner at Sisters of St. Joseph of Carondelet in Latham, NY. The author takes full responsibility for this content and did not receive honorari.